Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (TMA2019CDF-2662 Pfkelch13 emergence)
Received: 24 August 2022
Accepted: 20 May 2023
First Online: 26 May 2023
: The study protocol was reviewed and approved by Makerere University School of Biomedical Sciences Research Ethics Committee (SBS 803). The protocol was further reviewed and cleared by Uganda National Council of Science and Technology (UNCST), (HS1169ES). Administrative clearance was also obtained from the local district authorities in the study. In each drug outlet, a written informed consent was obtained from the pharmacist prior to data collection.
: Not applicable.
: The authors declare that they have no competing interests.